Prostate Cancer Trials Could Use Composite PSA/Bone Scan Endpoint, FDA's Hirschfeld Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Presenters at an FDA public workshop on prostate cancer clinical trial endpoints agree neither PSA nor bone scan alone would be an appropriate endpoint. PSA could be used to confirm a bone scan reading, Office of Cellular, Tissue & Gene Therapies Oncology Group Leader Hirschfeld suggests.